Abstract
LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have